Official websites use. Share sensitive information only on official, secure websites. Published Online: August 26, Author Contributions: Ms Jenei had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Conflict of Interest Disclosures: Dr Prasad reported receiving research funding from Arnold Ventures during the conduct of the study; and royalties from Johns Hopkins Press, Medscape, and MedPage; consulting fees from UnitedHealthcare; speaking fees from New Century Health and Evicore; and personal fees from Patreon Plenary Session podcast has Patreon backers outside the submitted work.
No other disclosures were reported. This cohort study reviews enrollment patterns of completed cancer drug trials over the past 20 years to compare sex-specific trial participation with current cancer incidence rates. Thirty years have passed since the enactment of the National Institutes of Health NIH Revitalization Act, which encouraged NIH-funded investigators to include adequate numbers of women in clinical studies.
As clinical trials become international in scope, we sought to evaluate the global movement toward this vision in oncology. In this cohort study, we reviewed enrollment patterns of completed cancer drug trials over the past 20 years to compare sex-specific trial participation to current cancer incidence rates.
Using data from the International Agency for Research on Cancer IARC , 6 we identified 6 common solid tumor types for women lung, colon, thyroid, melanoma, kidney, and pancreas.
